Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Aquestive Therapeutics, Inc.

Market Cap 501M 434M 400M 375M 701M 47.93B 716M 4.78B 1.85B 23.1B 1.88B 1.84B 80.33B P/E Ratio 2026 *
-9.85x
P/E Ratio 2027 * -10.3x
Enterprise Value 416M 361M 332M 311M 582M 39.79B 594M 3.97B 1.54B 19.18B 1.56B 1.53B 66.69B EV / Sales 2026 *
8.23x
EV / Sales 2027 * 6.96x
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day+3.88%
1 week+0.36%
Current month+3.36%
1 month-4.26%
3 months-2.69%
6 months-34.26%
Current year-35.68%
1 week 3.86
Extreme 3.855
4.16
1 month 3.85
Extreme 3.85
5.02
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-16
Director of Finance/CFO 67 2020-12-30
Compliance Officer - 2026-04-01
Director TitleAgeSince
Chairman 72 2024-03-31
Director/Board Member 60 2003-12-31
Director/Board Member 50 2022-05-16
Date Insider Type Main position Quantity % Market Cap.
06-07Tax

Executive/Senior Manager

-2,714 0.0022%
05-17Free

Compliance Officer

175,000 0.1408%
05-14Tax

General Counsel

-1,667 0.0013%
Change 5-day change 1-year change 3-year change Capi.($)
+3.88%+0.36%+21.85%+99.76% 501M
+1.67%+2.54%+42.70%+159.11% 1,013B
+0.40%+4.95%+54.23%+49.76% 574B
+0.14%+0.20%+17.70%+63.65% 397B
-0.37%+4.97%+21.24%+15.95% 324B
+0.85%+0.18%+24.50%+14.78% 280B
+2.10%+4.92%+25.30%+33.80% 273B
+3.73%+1.40%+20.09%+61.22% 182B
-0.19%-0.46%-45.32%-48.35% 194B
+3.31%-2.86%+14.80%+61.16% 151B
Average +1.53%+2.28%+19.71%+51.08% 338.91B
Weighted average by Cap. +1.11%+3.99%+29.27%+72.20%

Financials

2026 *2027 *
Net sales 50.52M 43.84M 40.41M 37.86M 70.74M 4.84B 72.22M 482M 187M 2.33B 190M 186M 8.11B 71.91M 62.41M 57.52M 53.9M 101M 6.89B 103M 686M 266M 3.32B 270M 264M 11.54B
Net income -50.65M -43.95M -40.51M -37.96M -70.93M -4.85B -72.41M -483M -187M -2.34B -190M -186M -8.13B -47.99M -41.65M -38.39M -35.97M -67.21M -4.6B -68.61M -458M -177M -2.22B -180M -176M -7.7B
Net Debt -85M -73.76M -67.99M -63.71M -119M -8.14B -122M -811M -314M -3.92B -319M -312M -13.64B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
26-06-11 4.160 $ +4.26% 747,158
26-06-10 3.990 $ 0.00% 1,588,511
26-06-09 3.990 $ +2.05% 1,395,356
26-06-08 3.910 $ -0.51% 1,539,363
26-06-05 3.930 $ -5.07% 1,234,997
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.990USD
Average target price
8.889USD
Spread / Average Target
+122.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!